MP-424 + peginterferon alfa-2a + ribavirin

MP-424 + peginterferon alfa-2a + ribavirin is a **triple drug combination** under investigation for the treatment of chronic hepatitis C virus (HCV) infection. Peginterferon alfa-2a is a recombinant interferon modified with polyethylene glycol to prolong its half-life and is used to stimulate antiviral immune responses. Ribavirin is a nucleoside analog with broad-spectrum antiviral activity, commonly paired with peginterferon alfa-2a to enhance efficacy. MP-424 is not well characterized in publicly available sources, but as implied by the context, it is likely an investigational direct-acting antiviral agent designed to target HCV replication through a unique mechanism distinct from interferon or ribavirin. Combination therapy aims to increase sustained virological response rates and reduce drug resistance by targeting multiple viral lifecycle steps simultaneously[1][2][3][5][6].